Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Q1 2023 Earnings Call. Please be advised that today’s conference is being recorded.
Coherus Biosciences Inc. (CHRS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 1,496,903 | $10,238,816 | +14% | 0% |
| 2. | 10,000,000 | $7,118,076 | 0% | ||
| 3. | D E Shaw D. E. Shaw | 998,378 | $6,828,905 | +39% | 0% |
| 4. | 7,306,000 | $5,158,036 | 0.05% | ||
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 572,928 | $3,918,828 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.42 | 3,700 | Officer | 35,118 | 2021-06-09 | Filing | |
| $13.50 | 425,926 | Director | 2,557,759 | 2014-11-12 | Filing | |
| $13.50 | 164,963 | Other | 3,042,019 | 2014-11-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.80 | 3,507 | Officer | 31,611 | 2021-10-15 | Filing | |
| $16.12 | 286,076 | Director | 0 | 2021-09-29 | Filing | |
| $17.17 | 48,329 | Director | 286,076 | 2021-09-28 | Filing | |
| $18.06 | 100,150 | Director | 334,405 | 2021-09-27 | Filing | |
| $13.56 | 31,054 | Officer, Director | 493,258 | 2021-06-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 14,397,565 | $98,479,343 | 0% | |
| 2. | 7,381,116 | $50,486,833 | 0.29% | |
| 3. | 6,136,925 | $41,976,567 | 0.01% | |
| 4. | 6,097,583 | $41,707,468 | 0% | |
| 5. | 5,982,535 | $40,920,000 | 0.02% |
News See All
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2022 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to Coherus Biosciences Fourth Quarter and Fiscal Year 2022 Earnings Conference Call.
Should You Invest in Coherus BioSciences (CHRS)?
Scout Investments, an affiliate of Carillon Tower Advisers, an investment management company, released its “Carillon Scout Small Cap Fund” third quarter 2022 investor letter.
Will Coherus BioSciences (CHRS) Stock Bounce Back?
Carillon Tower Advisers, an investment management company, released its “Carillon Scout Small Cap Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here.
10 Biotech Stocks to Buy Today According to Kerr Neilson's Platinum Asset Management
In this piece, we will take a look at the ten biotechnology stocks to buy today according to Kerr Neilson's Platinum Asset Management. If you want to skip the details about Mr.
10 Best Healthcare Stocks Under $20 According to Michael Castor's Sio Capital
In this article, we discuss the 10 best healthcare stocks under $20 according to Michael Castor's Sio Capital.
Hedge Funds Are Warming Up To Coherus Biosciences Inc (CHRS)
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a...
Hedge Funds Are Selling Coherus Biosciences Inc (CHRS)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC.
Did Hedge Funds Make The Right Call On Coherus Biosciences Inc (CHRS) ?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Aren't Done Buying Coherus Biosciences Inc (CHRS)
In this article we will check out the progression of hedge fund sentiment towards Coherus Biosciences Inc (NASDAQ:CHRS) and determine whether it is a good investment right now.
Billionaire Hedge Funds
